Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKG2D CAR-NK and CAR-T for Advanced Solid Tumors with Liver Metastases
NCT07021534Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Jun 2025
- Primary completion
- Dec 2026
- Modality
- CAR-T Cells, Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of NKG2D CAR NK cells and nkg2d car-t cells in solid tumor, liver metastases and colorectal cancer (CRC), sponsored by Zhejiang University. Primary endpoints: Treatment-Related Adverse Events at 6 months and Treatment-Related Serious Adverse Events at 6 months. Started Jun 2025; status: recruiting.
02
Drugs
NKG2D CAR NK cellsnkg2d car-t cells
03
Conditions
solid tumorliver metastasescolorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07021534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07021534.